RA
New data for Pfizer arthritis pill
September 18, 2012Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib
Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …
Pfizer’s RA pill impresses in Phase III
August 1, 2012Research and Development, Sales and Marketing FDA, JAK, Pfizer, RA
Pfizer’s investigational arthritis drug tofacitinib has beaten methotrexate in a head-to-head study. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is …
Humira powers ahead as Abbott prepares split
July 19, 2012Sales and Marketing AbbVie, Abbott, Humira, RA
Humira maintained its rapid growth in the second quarter, helping keep Abbott buoyant ahead of its split into two separate …
EMA clarifies antibodies development
June 20, 2012Manufacturing and Production, Research and Development, Sales and Marketing CMPHU, EMA, RA, antibodies
European regulators have issued final guidance on how pharma manufacturers should develop drugs containing monoclonal antibodies. Typically used in treatments …
RoActemra superior to Humira as single-agent therapy
June 7, 2012Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA
Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
Roche’s RoActemra beats Humira in arthritis study
March 5, 2012Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis
Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …
Abbott buys into Galapagos’ RA candidate
February 29, 2012Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF
Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …
Roche discontinues arthritis drug trials
May 20, 2010Sales and Marketing RA, Roche
Roche and Biogen Idec will discontinue clinical trials for rheumatoid arthritis drug ocrelizumab. Development of the RA treatment was halted …
Pfizer’s new RA treatment shows promise
November 11, 2009Research and Development, Sales and Marketing Pfizer, RA
Pfizer has announced data from two clinical studies of its developmental rheumatoid arthritis candidate.CP-690550 is the first in a new …
Simponi approved in Europe
October 8, 2009Sales and Marketing RA, Simponi, TNF
Rheumatic disease drug Simponi has received marketing approval for Europe, where it will be marketed by Schering-Plough.The drug is indicated …
Patients on Enbrel work longer, says study
September 7, 2009Research and Development, Sales and Marketing Enbrel, RA
Rheumatoid arthritis patients taking Enbrel are able to keep working for longer, according to a new study comparing its affects …
TNF blockers must carry children’s cancer warning
August 7, 2009Research and Development, Sales and Marketing FDA, RA, TNF
The FDA has ruled that TNF blocker drugs should carry new warnings of the increased risk of certain cancers for …
Centocor launches online arthritis talk show
August 4, 2009Medical Communications, Sales and Marketing Centacor, RA, US, digi
An online talk show for rheumatoid arthritis patients has been launched in the US with the aim of raising awareness …
Rheumatoid arthritis delays criticised
July 16, 2009Sales and Marketing NHS, RA
An official report into the treatment of people with rheumatoid arthritis (RA) has criticised a lack of co-ordination between different …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
